Publications by authors named "E Di Giacomo"
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.
Curr Oncol
December 2024
Background: There is ongoing discussion around the optimal course of treatment for metastatic colorectal cancer (mCRC) following the second line. Trifluridine/tipiracil (T) and regorafenib (R) have been the mainstay of therapy in this situation, as they both increased overall survival (OS) in comparison to a placebo. Despite the paucity of evidence, therapy rechallenge is also recognized as an option for practical use.
View Article and Find Full Text PDFArticle Synopsis
- ADHD affects about 7% of young people, and many women might be on medication like atomoxetine or methylphenidate during pregnancy, but the safety of these treatments for the fetus has not been well-studied.
- The objective of the study was to investigate the adverse effects on children whose mothers were treated with ADHD medications during pregnancy by analyzing data from various electronic databases.
- The analysis included ten studies with over 16 million pregnant women, and the findings indicated that there was no significant increase in miscarriages or congenital anomalies in the offspring of mothers who used these ADHD medications during pregnancy.
Background: Borderline personality disorder (BPD) is a complex mental health condition marked by instability in mood, relationships, self-image, and behavior. Individuals with BPD often struggle with intense emotions, impulsivity, and maintaining stable relationships. Oxytocin, known as the "love hormone" or "bonding hormone," plays a crucial role in social bonding, trust, empathy, and emotional regulation and its dysregulation may contribute to BPD difficulties.
View Article and Find Full Text PDFImportance: Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated.
Objective: To evaluate the association of immune checkpoint inhibitor (ICI)-based therapies vs BSC with overall survival (OS) of patients with uHCC and CP-B liver dysfunction.
Design, Setting, And Participants: This retrospective, multicenter, international clinical case series examined data of patients with CP-B with uHCC who were receiving first-line ICI-based regimens from September 2017 to December 2022 whose data were extracted from an international consortium and compared with a cohort of patients with CP-B receiving BSC.
Prader Willi syndrome, its psychiatric implications and their possible biological basis.
Eur Neuropsychopharmacol
September 2024